ArticleBrazilian oral research2026
Periostin and TGFβ1 levels in the saliva and gingival fluid of periodontitis patients: a cross-sectional study.
Article in Brazilian oral research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a chronic infectious disease characterized by the progressive destruction of tooth-supporting tissues. Identifying reliable, noninvasive biomarkers is essential for improving early detection and monitoring. This cross-sectional case‒control study evaluated clinical periodontal parameters and quantified periostin and transforming growth factor-beta 1 (TGF-β1) levels in the saliva and gingival crevicular fluid (GCF) of patients with stage I-II periodontitis and periodontally healthy controls. A total of 60 systemically healthy, nonsmoking participants aged 20-60 years were included (30 periodontitis patients and 30 periodontally healthy controls). Clinical periodontal parameters, including the plaque index, gingival index, probing depth, and clinical attachment level, were recorded. GCF and saliva samples were analyzed using an enzyme-linked immunosorbent assay (ELISA). Compared with periodontally healthy controls, stage I-II periodontitis patients had significantly greater numbers of clinical periodontal parameters (p < 0.001). They also had elevated salivary periostin (1,234.5 ± 505.82 ng/mL vs. 596.32 ± 320.47 ng/mL; p = 0.001), GCF TGF-β1 (10.14 ± 4.44 pg/mL vs. 6.50 ± 3.13 pg/mL; p = 0.003), and salivary TGF-β1 (31.59 ± 7.69 pg/mL vs. 20.25 ± 9.48 pg/mL; p = 0.001) levels. GCF periostin levels did not significantly differ between the periodontitis group (311.3 ± 210.3 ng/mL) and the periodontally healthy control group (208.6 ± 147.6 ng/mL) (p = 0.092). These findings suggest that salivary periostin and TGF-β1, together with GCF TGF-β1, may serve as promising noninvasive biomarkers for the diagnosis and monitoring of early-stage periodontitis. Salivary periostin showed particularly strong discriminatory potential and may hold promise for future chairside diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.